CHAPTER 1 BOTULINUM TOXIN MARKET: METHODOLOGY AND SCOPE
1.1 MARKET SEGMENTATION & SCOPE
1.1.1 PRODUCT TYPE
1.1.2 APPLICATION
1.1.3 END-USE
1.1.4 REGIONAL SCOPE
1.1.5 ESTIMATES AND FORECAST TIMELINE
1.2 RESEARCH METHODOLOGY
1.3 INFORMATION PROCUREMENT
1.3.1 PURCHASED DATABASE
1.3.2 GVR’S INTERNAL DATABASE
1.3.3 SECONDARY SOURCES
1.3.4 PRIMARY RESEARCH
1.3.5 DETAILS OF PRIMARY RESEARCH
1.4 INFORMATION OR DATA ANALYSIS
1.4.1 DATA ANALYSIS MODELS
1.5 MARKET FORMULATION & VALIDATION
1.6 MODEL DETAILS
1.6.1 COMMODITY FLOW ANALYSIS (MODEL 1)
1.7 LIST OF SECONDARY SOURCES
1.8 LIST OF PRIMARY SOURCES
1.9 LIST OF ABBREVIATIONS
1.10 OBJECTIVES
1.10.1 OBJECTIVE - 1
1.10.2 OBJECTIVE - 2
1.10.3 OBJECTIVE - 3
CHAPTER 2 BOTULINUM TOXIN MARKET: EXECUTIVE SUMMARY
2.1 MARKET SNAPSHOT
2.2 SEGMENT SNAPSHOT
2.3 COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3 BOTULINUM TOXIN MARKET: VARIABLES, TRENDS, & SCOPE
3.1 MARKET SEGMENTATION AND SCOPE
3.2 MARKET DYNAMICS
3.2.1 MARKET DRIVER ANALYSIS
3.2.2.1 INCREASING NUMBER OF PATIENTS HAVING NEUROLOGICAL DISORDERS
3.2.2.2 RISING PREFERENCE FOR NON-INVASIVE OR MINIMALLY INVASIVE PROCEDURES
3.2.2.3 INCREASING CONCERN REGARDING AESTHETIC APPEARANCE IN 40-54 AGE GROUP HAS INCREASED THE ADOPTION RATE
3.2.2 MARKET RESTRAINT ANALYSIS
3.2.2.1 HIGH COST OF COSMETIC PROCEDURE
3.3 BOTULINUM TOXIN: MARKET ANALYSIS TOOLS
3.3.1 INDUSTRY ANALYSIS - PORTER’S
3.3.2 PESTEL ANALYSIS
3.4 COVID-19 IMPACT ANALYSIS
CHAPTER 4 BOTULINUM TOXIN MARKET: PRODUCT TYPE SEGMENT ANALYSIS
4.1 BOTULINUM TOXIN: PRODUCT TYPE MARKET SHARE ANALYSIS, 2025 & 2033
4.2 TYPE A
4.2.1 TYPE A MARKET ESTIMATES AND FORECASTS, 2024 - 2033
4.2.1.1 BOTOX
4.2.1.2 DYSPORT
4.2.1.3 XEOMIN
4.2.1.4 OTHERS
4.2.2 TYPE B
4.2.2.1 TYPE B MARKET ESTIMATES AND FORECASTS, 2024 - 2033
CHAPTER 5 BOTULINUM TOXIN MARKET: APPLICATION SEGMENT ANALYSIS
5.1 BOTULINUM TOXIN: APPLICATION MARKET SHARE ANALYSIS, 2025 & 2033
5.2 THERAPEUTIC
5.2.1 THERAPEUTIC MARKET ESTIMATES AND FORECASTS, 2024 - 2033
5.2.1.1 CHRONIC MIGRAINE
5.2.1.2 OVERACTIVE BLADDER
5.2.1.3 CERVICAL DYSTONIA
5.2.1.4 SPASTICITY
5.2.1.5 OTHERS
5.3 AESTHETIC
5.3.1 AESTHETIC MARKET ESTIMATES AND FORECASTS, 2024 - 2033
5.3.1.1 GLABELLAR LINES
5.3.1.2 CROW'S FEET
5.3.1.3 FOREHEAD LINES
5.3.1.4 OTHERS
CHAPTER 6 BOTULINUM TOXIN MARKET: END-USE SEGMENT ANALYSIS
6.1 BOTULINUM TOXIN: END-USE MARKET SHARE ANALYSIS, 2025 & 2033
6.2 HOSPITALS
6.2.1 HOSPITALS MARKET ESTIMATES AND FORECASTS, 2024 - 2033
6.3 DERMATOLOGY CLINICS
6.3.1 DERMATOLOGY CLINICS MARKET ESTIMATES AND FORECASTS, 2024 - 2033
6.4 SPAS AND COSMETIC CENTERS
6.4.1 SPAS AND COSMETIC CENTERS MARKET ESTIMATES AND FORECASTS, 2024 - 2033
CHAPTER 7 BOTULINUM TOXIN MARKET: REGIONAL ANALYSIS
7.1 BOTULINUM TOXIN: REGIONAL MARKET SHARE ANALYSIS, 2025 & 2033
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA BOTULINUM TOXIN MARKET, 2024 - 2033
7.2.2 U.S.
7.2.2.1 KEY COUNTRY DYNAMICS
7.2.2.2 U.S. BOTULINUM TOXIN MARKET, 2024 - 2033
7.2.3 CANADA
7.2.3.1 KEY COUNTRY DYNAMICS
7.2.3.2 CANADA BOTULINUM TOXIN MARKET, 2024 - 2033
7.3 EUROPE
7.3.1 EUROPE BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.2 UK
7.3.2.1 KEY COUNTRY DYNAMICS
7.3.2.2 UK BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.3 GERMANY
7.3.3.1 KEY COUNTRY DYNAMICS
7.3.3.2 GERMANY BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.4 FRANCE
7.3.4.1 KEY COUNTRY DYNAMICS
7.3.4.2 FRANCE BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.5 ITALY
7.3.5.1 KEY COUNTRY DYNAMICS
7.3.5.2 ITALY BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.6 SPAIN
7.3.6.1 KEY COUNTRY DYNAMICS
7.3.6.2 SPAIN BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.7 DENMARK
7.3.7.1 KEY COUNTRY DYNAMICS
7.3.7.2 DENMARK BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.8 SWEDEN
7.3.8.1 KEY COUNTRY DYNAMICS
7.3.8.2 SWEDEN BOTULINUM TOXIN MARKET, 2024 - 2033
7.3.9 NORWAY
7.3.9.1 KEY COUNTRY DYNAMICS
7.3.9.2 NORWAY BOTULINUM TOXIN MARKET, 2024 - 2033
7.4 ASIA PACIFIC
7.4.1 ASIA PACIFIC BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.2 CHINA
7.4.2.1 KEY COUNTRY DYNAMICS
7.4.2.2 CHINA BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.3 INDIA
7.4.3.1 KEY COUNTRY DYNAMICS
7.4.3.2 INDIA BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.4 JAPAN
7.4.4.1 KEY COUNTRY DYNAMICS
7.4.4.2 JAPAN BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.5 SOUTH KOREA
7.4.5.1 KEY COUNTRY DYNAMICS
7.4.5.2 SOUTH KOREA BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.6 AUSTRALIA
7.4.6.1 KEY COUNTRY DYNAMICS
7.4.6.2 AUSTRALIA BOTULINUM TOXIN MARKET, 2024 - 2033
7.4.7 THAILAND
7.4.7.1 KEY COUNTRY DYNAMICS
7.4.7.2 THAILAND BOTULINUM TOXIN MARKET, 2024 - 2033
7.5 LATIN AMERICA
7.5.1 LATIN AMERICA BOTULINUM TOXIN MARKET, 2024 - 2033
7.5.2 BRAZIL
7.5.2.1 KEY COUNTRY DYNAMICS
7.5.2.2 BRAZIL BOTULINUM TOXIN MARKET, 2024 - 2033
7.5.3 MEXICO
7.5.3.1 KEY COUNTRY DYNAMICS
7.5.3.2 MEXICO BOTULINUM TOXIN MARKET, 2024 - 2033
7.5.4 ARGENTINA
7.6.4.1 KEY COUNTRY DYNAMICS
7.6.4.2 ARGENTINA BOTULINUM TOXIN MARKET, 2024 - 2033
7.6 MEA
7.6.1 MEA BOTULINUM TOXIN MARKET, 2024 - 2033
7.6.2 SOUTH AFRICA
7.6.2.1 KEY COUNTRY DYNAMICS
7.6.2.2 SOUTH AFRICA BOTULINUM TOXIN MARKET, 2024 - 2033
7.6.3 SAUDI ARABIA
7.6.3.1 KEY COUNTRY DYNAMICS
7.6.3.2 SAUDI ARABIA BOTULINUM TOXIN MARKET, 2024 - 2033
7.6.4 UAE
7.6.4.1 KEY COUNTRY DYNAMICS
7.6.4.2 UAE BOTULINUM TOXIN MARKET, 2024 - 2033
7.6.5 KUWAIT
7.6.5.1 KEY COUNTRY DYNAMICS
7.6.5.2 KUWAIT BOTULINUM TOXIN MARKET, 2024 - 2033
CHAPTER 8 COMPANY PROFILES
8.1. RECENT DEVELOPMENTS & IMPACT ANALYSIS, BY KEY MARKET PARTICIPANTS
8.2. BOTULINUM TOXIN- MARKET SHARE ANALYSIS
8.3. EISAI CO., LTD
8.3.1 COMPANY OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT BENCHMARKING
8.3.4 STRATEGIC INITIATIVES
8.4. EVOLUS, INC.,.
8.4.1 COMPANY OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT BENCHMARKING
8.4.4 STRATEGIC INITIATIVES
8.5 GALDERMA LABORATORIES.
8.5.1 COMPANY OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT BENCHMARKING
8.5.4 STRATEGIC INITIATIVES
8.6 HUGEL, INC. (KOREA)
8.6.1 COMPANY OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 STRATEGIC INITIATIVES
8.7 HUGH SOURCE (INTERNATIONAL) LTD.
8.7.1 COMPANY OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT BENCHMARKING
8.7.4 STRATEGIC INITIATIVES
8.8 IPSEN PHARMA
8.8.1 COMPANY OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT BENCHMARKING
8.8.4 STRATEGIC INITIATIVES
8.9 LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. (CHINA)
8.9.1 COMPANY OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT BENCHMARKING
8.9.4 STRATEGIC INITIATIVES
8.10 MEDY-TOX, INC.
8.10.1 COMPANY OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT BENCHMARKING
8.10.4 STRATEGIC INITIATIVES
8.11 MERZ PHARMA GMBH & CO. KGAA
8.11.1 COMPANY OVERVIEW
8.11.2 FINANCIAL PERFORMANCE
8.11.3 PRODUCT BENCHMARKING
8.11.4 STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
